Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Commitment and Contingent Liabilities (Tables)

v3.8.0.1
Commitment and Contingent Liabilities (Tables)
12 Months Ended
Dec. 31, 2017
Commitment and Contingent Liabilities [Abstract]  
Schedule of royalty rate

On net sales of:   %  
● leukemia related products     3.0  
● other products     2.5  
● in certain limited circumstances, rates may be reduced to     2.0  

 

On fixed sublicense income (with no sublicense income on sales by sub licensee):   %  
● leukemia related products     20.0  
● other products     15.0  

 

On fixed sublicense income (with sublicense income on sales by sub licensee):   %  
● leukemia related products     10.0  
● other products     7.5